PFS Partners’s Akebia Therapeutics AKBA Stock Holding History

PFS Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-187	Closed	-$423	–	352
2021 Q4	$423	Buy	+187	New	+$510	﹤0.01%	336

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

PFS Partners's AKBA Position: Q1 2022 in Review

PFS Partners sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 187 shares — an estimated $423 sold.

PFS Partners first reported a position in AKBA in Q4 2021 and held it in 1 quarter. The position peaked at $423 in Q4 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

PFS Partners reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
PFS Partners sold 187 Akebia Therapeutics shares in Q1 2022, an estimated $423.
PFS Partners first reported a position in Akebia Therapeutics in Q4 2021 and held it in 1 quarter.
PFS Partners's Akebia Therapeutics position peaked at $423 in Q4 2021.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on PFS Partners's 13F filing for Q1 2022, filed 1 Dec 2023.